Relationship of Microsatellite Instability to Mismatch Repair Deficiency in Malignant Tumors of Dogs

Overview

Journal J Vet Intern Med

Specialties General Medicine
Veterinary Medicine

Date 2022 Aug 12

PMID 35959511

Authors

Sakuya Inanaga

Masaya Igase

Yusuke Sakai

Kenji Hagimori

Hiroshi Sunahara

Hiro Horikirizono

Kazuhito Itamoto

Kenji Baba

Yoshiharu Ohsato

Takuya Mizuno

Affiliations

Soon will be listed here.

Abstract

Background: Microsatellite instability (MSI) is a type of genomic instability caused by mismatch repair deficiency (dMMR) in tumors. Studies on dMMR/MSI are limited, and the relationship between dMMR and MSI is unknown in tumors of dogs.

Objectives: We aimed to identify the frequency of dMMR/MSI by tumor type and evaluate the relationship between dMMR and MSI in tumors of dogs.

Animals: In total, 101 dogs with 11 types of malignant tumors were included.

Methods: We extracted DNA from fresh normal and tumor tissues. Twelve microsatellite loci from both normal and tumor DNA were amplified by PCR and detected by capillary electrophoresis. Each microsatellite (MS) was defined as MSI if a difference in product size between the tumor and normal DNA was detected. The dMMR was evaluated by immunohistochemistry with formalin-fixed paraffin-embedded tumor tissues. Next, we confirmed whether dMMR induces MSI by serial passaging of MMR gene knockout cell lines for 3 months.

Results: Microsatellite instability was detected frequently in oral malignant melanoma. The number of MSI-positive markers was higher in cases with dMMR than in those with proficient MMR (P < .0001). Statistical analysis indicated that the occurrence of MSI in FH2305 might have relevance to dMMR. Furthermore, MSI occurred in dMMR cell lines 3 months after passaging.

Conclusions And Clinical Importance: Microsatellite instability and dMMR more frequently were found in oral malignant melanoma than in other tumors, and dMMR has relevance to MSI in both clinical cases and cell lines.

Citing Articles

Is increased mutation driving genetic diversity in dogs within the Chornobyl exclusion zone?.

Dillon M, Dickey A, Roberts R, Betz J, Mousseau T, Kleiman N PLoS One. 2024; 19(12):e0315244.

PMID: 39729458 PMC: 11676578. DOI: 10.1371/journal.pone.0315244.

Proof-of-concept study of the caninized anti-canine programmed death 1 antibody in dogs with advanced non-oral malignant melanoma solid tumors.

Igase M, Inanaga S, Nishibori S, Itamoto K, Sunahara H, Nemoto Y J Vet Sci. 2024; 25(1):e15.

PMID: 38311328 PMC: 10839171. DOI: 10.4142/jvs.23144.

Relationship of microsatellite instability to mismatch repair deficiency in malignant tumors of dogs.

Inanaga S, Igase M, Sakai Y, Hagimori K, Sunahara H, Horikirizono H J Vet Intern Med. 2022; 36(5):1760-1769.

PMID: 35959511 PMC: 9511092. DOI: 10.1111/jvim.16454.

References

Maekawa N, Konnai S, Nishimura M, Kagawa Y, Takagi S, Hosoya K . PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma. NPJ Precis Oncol. 2021; 5(1):10. PMC: 7881100. DOI: 10.1038/s41698-021-00147-6. View

Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff J . Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res. 1997; 57(21):4749-56. View

Igase M, Nemoto Y, Itamoto K, Tani K, Nakaichi M, Sakurai M . A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs. Sci Rep. 2020; 10(1):18311. PMC: 7591904. DOI: 10.1038/s41598-020-75533-4. View

Le D, Kim T, Van Cutsem E, Geva R, Jager D, Hara H . Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2019; 38(1):11-19. PMC: 7031958. DOI: 10.1200/JCO.19.02107. View

Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X . Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer. 2018; 17(1):129. PMC: 6107958. DOI: 10.1186/s12943-018-0864-3. View

Marcus L, Lemery S, Keegan P, Pazdur R . FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Clin Cancer Res. 2019; 25(13):3753-3758. DOI: 10.1158/1078-0432.CCR-18-4070. View

Inanaga S, Igase M, Sakai Y, Hagimori K, Sunahara H, Horikirizono H . Relationship of microsatellite instability to mismatch repair deficiency in malignant tumors of dogs. J Vet Intern Med. 2022; 36(5):1760-1769. PMC: 9511092. DOI: 10.1111/jvim.16454. View

Alsaihati B, Ho K, Watson J, Feng Y, Wang T, Dobbin K . Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds. Nat Commun. 2021; 12(1):4670. PMC: 8333103. DOI: 10.1038/s41467-021-24836-9. View

Boland C, Thibodeau S, Hamilton S, Sidransky D, Eshleman J, Burt R . A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998; 58(22):5248-57. View

10.

Guyon R, Lorentzen T, Hitte C, Kim L, Cadieu E, Parker H . A 1-Mb resolution radiation hybrid map of the canine genome. Proc Natl Acad Sci U S A. 2003; 100(9):5296-301. PMC: 154339. DOI: 10.1073/pnas.0831002100. View

11.

Loechel R, Venta P, Yuzbasiyan-Gurkan V, Brewer G . Chromosomal assignment of seven genes on canine chromosomes by fluorescence in situ hybridization. Mamm Genome. 1996; 7(4):268-70. DOI: 10.1007/s003359900080. View

12.

Mandal R, Samstein R, Lee K, Havel J, Wang H, Krishna C . Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science. 2019; 364(6439):485-491. PMC: 6685207. DOI: 10.1126/science.aau0447. View

13.

Tautz D . Notes on the definition and nomenclature of tandemly repetitive DNA sequences. EXS. 1993; 67:21-8. DOI: 10.1007/978-3-0348-8583-6_2. View

14.

Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View

15.

Cicek M, Lindor N, Gallinger S, Bapat B, Hopper J, Jenkins M . Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors results from the Colon Cancer Family Registry. J Mol Diagn. 2011; 13(3):271-81. PMC: 3077724. DOI: 10.1016/j.jmoldx.2010.12.004. View

16.

Eshleman J, Markowitz S . Mismatch repair defects in human carcinogenesis. Hum Mol Genet. 1996; 5 Spec No:1489-94. DOI: 10.1093/hmg/5.supplement_1.1489. View

17.

Bronner C, Baker S, Morrison P, Warren G, Smith L, Lescoe M . Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature. 1994; 368(6468):258-61. DOI: 10.1038/368258a0. View

18.

Bocker T, Diermann J, Friedl W, Gebert J, Holinski-Feder E, Karner-Hanusch J . Microsatellite instability analysis: a multicenter study for reliability and quality control. Cancer Res. 1997; 57(21):4739-43. View

19.

OKeefe C, McDevitt M, Maciejewski J . Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies. Blood. 2010; 115(14):2731-9. PMC: 2854422. DOI: 10.1182/blood-2009-10-201848. View

20.

Igase M, Shibutani S, Kurogouchi Y, Fujiki N, Hwang C, Coffey M . Combination Therapy with Reovirus and ATM Inhibitor Enhances Cell Death and Virus Replication in Canine Melanoma. Mol Ther Oncolytics. 2019; 15:49-59. PMC: 6804779. DOI: 10.1016/j.omto.2019.08.003. View